GW6471
GW6471 物理性質
- 比重(密度) :
- 1.204±0.06 g/cm3(Predicted)
- 貯蔵温度 :
- 2-8°C
- 溶解性:
- DMSO: 15 mg/mL
- 外見 :
- 個体
- 酸解離定数(Pka):
- 15.90±0.46(Predicted)
- 色:
- オフホワイト
メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01TOC4618 |
GW 6471 |
880635-03-0 |
10mg |
¥81000 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01TRCG931200 |
GW6471
GW 6471 |
880635-03-0 |
100mg |
¥2936700 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01TRCG931200 |
GW6471
GW 6471 |
880635-03-0 |
10mg |
¥243100 |
2023-06-01 |
購入 |
Sigma-Aldrich Japan
|
G5045 |
≥98% (HPLC)
GW6471 ≥98% (HPLC) |
880635-03-0 |
5mg |
¥56200 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01TOC4618 |
GW 6471 |
880635-03-0 |
50mg |
¥341000 |
2024-03-01 |
購入 |
GW6471 化学特性,用途語,生産方法
使用
GW 6471 is a peroxisome proliferator-activated receptor α (PPARα) antagonist. GW 6471 has been shown to enhance the binding affinity of the PPARα ligand-binding domain to the co-repressor proteins SMRT and NCoR.
一般的な説明
GW6471 prevents apoptosis and cell cycle arrest at G
0/G
1 in renal cell carcinoma. It reduces enhanced fatty acid oxidation and oxidative phosphorylation associated with glycolysis inhibition.
Biochem/physiol Actions
GW6471 is a PPARα antagonist, which completely inhibits GW409544-induced activation of PPARα with an IC50 = 0.24 μM. GW6471 induces a PPARα conformation that interacts efficiently with co-repressors.
GW6471 上流と下流の製品情報
原材料
準備製品
GW6471 生産企業
Global( 116)Suppliers
880635-03-0(GW6471)キーワード:
- 880635-03-0
- N-((2S)-2-(((1Z)-1-METHYL-3-OXO-3-(4-(TRIFLUOROMETHYL)PHENYL)PROP-1-ENYL)AMINO)-3-(4-(2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHOXY)PHENYL)PROPYL)PROPANAMIDE
- [(2S)-2-[[(1Z)-1-METHYL-3-OXO-3-[4-(TRIFLUOROMETHYL)PHENYL]-1-PROPENYL]AMINO]-3-[4-[2-(5-METHYL-2-PHENYL-4-OXAZOLYL)ETHOXY]PHENYL]PROPYL]-CARBAMIC ACID ETHYL ESTER
- GW 6471
- Propanamide, N-[(2S)-2-[[(1Z)-1-methyl-3-oxo-3-[4-(trifluoromethyl)phenyl]-1-propen-1-yl]amino]-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propyl]-
- GW 6471 USP/EP/BP
- (S,Z)-N-(3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-((4-oxo-4-(4-(trifluoromethyl)phenyl)but-2-en-2-yl)amino)propyl)propionamide
- N-[(2S)-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}-2-{[(2Z)-4-oxo-4-[4-(trifluoromethyl)phenyl]but-2-en-2-yl]amino}propyl]propanamide
- GW 6471, PPAR alpha antagonist
- GW6471, 10 mM in DMSO
- GW6471
- N-[(2S)-3-{4-[2-(5-メチル-2-フェニル-1,3-オキサゾール-4-イル)エトキシ]フェニル}-2-{[(2Z)-4-オキソ-4-[4-(トリフルオロメチル)フェニル]ブタ-2-エン-2-イル]アミノ}プロピル]プロパンアミド
- GW-6471
- N-[(2S)-2-[[(1Z)-1-メチル-3-オキソ-3-[4-(トリフルオロメチル)フェニル]-1-プロペニル]アミノ]-3-[4-[2-(2-フェニル-5-メチル-4-オキサゾリル)エトキシ]フェニル]プロピル]プロピオンアミド